0.60
0.60 (0%)
As of Nov 29, 2024
Telesis Bio Inc. [TBIO]
Source:
Company Overview
Telesis Bio Inc is a leader in automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA and short oligonucleotides, such as CRISPR guides, that are ready to use in many downstream synthetic biology enabled markets.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 858-228-4115 |
| Industry | |
| CEO | Todd R. Nelson |
| Website | www.telesisbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.6 |
| Operating Profit | $-5.5 |
| Net Income | $-6.6 |
| Net Cash | $2.1 |
Profit Ratios
| Gross Margin | $1 |
| Operating Margin | -349.7 |
| Profit as % of Revenues | -15.2% |
| Profit as % of Assets | -50.5% |
| Profit as % of Stockholder Equity | 24.4% |
Management Effectiveness
| Return on Equity | 24.4% |
| Return on Assets | -26.9% |
| Turnover Ratio | 11.9% |
| EBITA | $-5.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $24.7 |
| Total Liabilities | $20.9 |
| Operating Cash Flow | $-15.5 |
| Investing Cash Flow | $17.8 |
| Financing Cash Flow | $-0.2 |
